Ally Therapeutics
Cambridge
About Ally Therapeutics
Ally Therapeutics solves the immune response barriers for gene therapy. They are dedicated to solving the immune response issues that limit the safety and efficacy of in vivo gene therapies. It is backed by ARCH, Alta, and UCB Ventures. The company is a new biotech company based in Cambridge, Massachusetts, and was founded in 2018.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $10.0M
- Last round: Series Unknown (Jul 2019)
- Website: allytx.com
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/ally-therapeutics-109988 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.